Edwards Lifesciences raises 2026 sales and TAVR growth guidance
Edwards Lifesciences increased its full-year 2026 sales growth rate guidance to 10% to 11% from 9% to 11%, TAVR product group sales growth guidance to 8% to 9% from 7% to 9%, and TMTT product group sales guidance to $760 to $780 million from $740 to $780 million. The company reaffirmed adjusted EPS guidance of $2.95 to $3.05 for the full year despite assuming a higher effective tax rate. Second quarter sales grew 13.6% to $1.74 billion on a reported basis and 12.5% on a constant currency basis.
- Total company constant currency sales growth guidance raised to 10% to 11% from 9% to 11%
- TAVR constant currency sales growth guidance raised to 8% to 9% from 7% to 9%
- TMTT sales guidance raised to $760 to $780 million from $740 to $780 million
- Q2 sales grew 13.6% to $1.74 billion reported; 12.5% constant currency
- Q2 TAVR sales grew 11.3% to $1.26 billion reported; 10.5% constant currency
- Q2 TMTT sales were $195.9 million, up 47.3% reported; 44.8% constant currency
- Adjusted EPS guidance reaffirmed at $2.95 to $3.05, growing 17% at midpoint
- Gross profit margin expected at lower end of 78% to 79% guidance due to FX headwinds
- Expected tax rate at high end of 16% to 19% range
- Q3 2026 projected total sales $1.63 to $1.71 billion; adjusted EPS $0.71 to $0.77
Edwards raised its core revenue and product-group growth targets mid-year, signaling accelerating structural heart procedure adoption and successful portfolio expansion, while maintaining flat adjusted EPS guidance despite a higher tax headwind—indicating confidence in operational execution but offsetting tax pressure.
Derived from 8-K filed 2026-07-23. Not investment advice. Figures are extracted from the filing; prose is AI-assisted. View the source filing on SEC.gov →